Dear Esteemed Members and Colleagues,
It is with the great honor and gratitude that I address you today as the 20th President of the Korean Urological Oncology Society.

Since the first "Founding Assembly and First Academic Conference of the Korean Urological Oncology Society" was held on February 23, 1991, our society has grown into the most pioneering and progressive organization in the field of urology, thanks to the dedication and support of our esteemed members.

However, the field of urologic oncology has seen rapid advancements in surgical and pharmacological treatments, with standard treatment guidelines evolving every year. In particular, the introduction of new drugs has accelerated clinical research, making it increasingly challenging for our members to keep up with the latest developments in the diagnosis and treatment of urologic cancers.
Furthermore, unresolved conflicts between the medical community and policymakers have created an uncertain and difficult environment for our members, adding to their challenges and concerns.